MDM2 inhibitors in the search for an optimized neovascular age-related macular degeneration treatment

References

• Klein R, Chou CF, Klein BE. Prevalence of age-related macular degeneration in the US population. Arch Ophthalmol 2011;129(1):75-80
   PubMedGoogle Scholar
• Klein R, Klein BE, Linton KL. Prevalence of age-related maculopathy. The Beaver Dam Eye Study. Ophthalmology 1992;99(6):933-43
   PubMed Web of Science ®Google Scholar
• Evans J, Wormald R. Is the incidence of registrable age-related macular degeneration increasing? Br J Ophthalmology 1996;80(1):9-14
   PubMed Web of Science ®Google Scholar
• Schmier JK, Levine JA. Economic impact of progression of age-related macular degeneration. US Ophthalmic Review 2013;6(1):52-7
   Google Scholar
• Ambati J, Ambati BK, Yoo SH, et al. Age-related macular degeneration: etiology, pathogenesis, and therapeutic strategies. Surv Ophthalmol 2003;48(3):257-93
   PubMed Web of Science ®Google Scholar
• Swaroop A, Branham KE, Chen W, Abecasis G. Genetic susceptibility to age-related macular degeneration: a paradigm for dissecting complex disease traits. Hum Mol Genet 2007;16(R2):R174-82
   Google Scholar
• Donders FC. Beiträge zur pathologischen Anatomie des Auges. Graefes Arch Clin Exp Ophthalmol Springer-Verlag 1855;2(1):106-18
   Google Scholar
• Ahn JK, Moon HJ. Changes in aqueous vascular endothelial growth factor and pigment epithelium-derived factor after ranibizumab alone or combined with verteporfin for exudative age-related macular degeneration. Am J Ophthalmol 2009;148(5):718-24
   PubMed Web of Science ®Google Scholar
• Tong JP, Chan WM, Liu DTL, et al. Aqueous humor levels of vascular endothelial growth factor and pigment epithelium–derived factor in polypoidal choroidal vasculopathy and choroidal neovascularization. Am J Ophthalmol 2006;141(3):456-62
   PubMed Web of Science ®Google Scholar
• Okamoto N, Tobe T, Hackett SF, et al. Transgenic mice with increased expression of vascular endothelial growth factor in the retina: a new model of intraretinal and subretinal neovascularization. Am J Pathol 1997;151(1):281-91
   PubMed Web of Science ®Google Scholar
• Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006;355(14):1419-31
   PubMed Web of Science ®Google Scholar
• CATT Research Group. Martin DF, Maguire MG, Ying GS, et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011;364(20):1897-908
   PubMed Web of Science ®Google Scholar
• Rofagha S, Bhisitkul RB, Boyer DS, et al. Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON. Ophthalmology 2013;
   PubMedGoogle Scholar
• Rosenfeld PJ, Shapiro H, Tuomi L, et al. Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials. Ophthalmology 2011;118(3):523-30
   PubMed Web of Science ®Google Scholar
• Tolentino M. Systemic and ocular safety of intravitreal anti-VEGF therapies for ocular neovascular disease. Surv Ophthalmol 2011;56(2):95-113
   PubMed Web of Science ®Google Scholar
• Tseng JJ, Vance SK, Torre Della KE, et al. Sustained increased intraocular pressure related to intravitreal antivascular endothelial growth factor therapy for neovascular age-related macular degeneration. J Glaucoma 2012;21(4):241-7
   PubMed Web of Science ®Google Scholar
• McCannel CA. Meta-analysis of endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents: causative organisms and possible prevention strategies. Retina 2011;31:654-66
   PubMed Web of Science ®Google Scholar
• Spaide RF. Rationale for combination therapy in age-related macular degeneration. Retina (Philadelphia, Pa) 2009(Suppl):S5–S7
   Google Scholar
• Kaiser PK. Emerging therapies for neovascular age-related macular degeneration: drugs in the pipeline. Ophthalmology 2013;120(5 Suppl):S11-15
   Web of Science ®Google Scholar
• Englander M, Kaiser PK. Combination therapy for the treatment of neovascular age-related macular degeneration. Curr Opin Ophthalmol 2013;24(3):233-8
   PubMed Web of Science ®Google Scholar
• Ruiz-Moreno JM, Montero JA. Subretinal fibrosis after photodynamic therapy in subfoveal choroidal neovascularisation in highly myopic eyes. Br J Ophthalmol 2003;87(7):856
   PubMed Web of Science ®Google Scholar
• Kishan AU, Modjtahedi BS, Morse LS, Lee P. Radiation therapy for neovascular age-related macular degeneration. Int J Radiat Oncol Biol Phys 2013;85(3):583-97
   PubMed Web of Science ®Google Scholar
• Guyton JS, Reese AB. Use of roentgen therapy for retinal diseases characterized by new-formed blood vessels; Eales disease; retinitis proliferans. Arch Ophthalmol 1948;40(4):389-412
   Google Scholar
• Jackson TL, Chakravarthy U, Kaiser PK, et al. Stereotactic radiotherapy for neovascular age-related macular degeneration. Ophthalmology 2013;120(9):1893-900
   PubMed Web of Science ®Google Scholar
• Rödel F, Keilholz L, Herrmann M, et al. Radiobiological mechanisms in inflammatory diseases of low-dose radiation therapy. Int J Radiat Biol 2007;83(6):357-66
   PubMed Web of Science ®Google Scholar
• Hadjimichael C, Kardamakis D, Papaioannou S. Irradiation dose-response effects on angiogenesis and involvement of nitric oxide. Anticancer Res 2005;25(2A):1059-65
   PubMed Web of Science ®Google Scholar
• Jackson TL, Dugel PU, Bebchuk JD, et al. Epimacular brachytherapy for neovascular age-related macular degeneration (CABERNET). Ophthalmology 2013;120(8):1597-603
   PubMed Web of Science ®Google Scholar
• Bhattacharya S, Ray RM, Chaum E, et al. Inhibition of MDM2 sensitized human retinal pigment epithelial cells to apoptosis. Invest Ophthalmol Vis Sci 2011;52(6):3368-80
   PubMed Web of Science ®Google Scholar
• Graves B, Thompson T, Xia M, et al. Activation of the p53 pathway by small-molecule-induced MDM2 and MDMX dimerization. Proc Natl Acad Sci USA 2012;109(29):11788-93
   PubMed Web of Science ®Google Scholar
• Bhattacharya S, Chaum E, Johnson DA, Johnson LR. Age-related susceptibility to apoptosis in human retinal pigment epithelial cells is triggered by disruption of p53-MDM2 association. Invest Ophthalmol Vis Sci 2012;53(13):8350-66
   PubMed Web of Science ®Google Scholar
• Vassilev LT. In Vivo Activation of the p53 Pathway by Small-Molecule Antagonists of MDM2. Science 2004;303(5659):844-8
   PubMed Web of Science ®Google Scholar
• Shangary S, Wang S. Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy. Annu Rev Pharmacol Toxicol 2009;49:223-41
   PubMed Web of Science ®Google Scholar
• Hardcastle IR, Liu J, Valeur E, et al. Isoindolinone inhibitors of the murine double minute 2 (MDM2)-p53 protein-protein interaction: structure-activity studies leading to improved potency. J Med Chem 2011;54(5):1233-43
   PubMed Web of Science ®Google Scholar
• Vuong L, Conley SM, Al-Ubaidi MR. Expression and role of p53 in the retina. Invest Ophthalmol Vis Sci 2012;53(3):1362-9
   PubMed Web of Science ®Google Scholar
• Chavala SH, Kim Y, Tudisco L, et al. Retinal angiogénesis suppression through small molecule activation of p53. J Clin Invest 2013;123(10):4170-81
   PubMed Web of Science ®Google Scholar
• Ding Q, Zhang Z, Liu JJ, et al. Discovery of RG7388, a potent and selective p53–MDM2 inhibitor in clinical development. J Med Chem 2013;56(14):5979-83
   PubMed Web of Science ®Google Scholar
• Zhao Y, Yu S, Sun W, et al. A potent small-molecule inhibitor of the MDM2–p53 interaction (MI-888) achieved complete and durable tumor regression in mice. J Med Chem 2013;56(13):5553-61
   PubMed Web of Science ®Google Scholar
• Bernard D, Zhao Y, Wang S. AM-8553: a novel MDM2 inhibitor with a promising outlook for potential clinical development. J Med Chem 2012;55(11):4934-5
   PubMed Web of Science ®Google Scholar
• Lee YM, Lim JH, Chun YS, et al. Nutlin-3, an Hdm2 antagonist, inhibits tumor adaptation to hypoxia by stimulating the FIH-mediated inactivation of HIF-1alpha. Carcinogenesis 2009;30(10):1768-75
   PubMed Web of Science ®Google Scholar
• LaRusch GA, Jackson MW, Dunbar JD, et al. Nutlin3 blocks vascular endothelial growth factor induction by preventing the interaction between hypoxia inducible factor 1 and Hdm2. Cancer Res 2007;67(2):450-4
   PubMed Web of Science ®Google Scholar
• Zhang F, Tagen M, Throm S, et al. Whole-body physiologically based pharmacokinetic model for nutlin-3a in mice after intravenous and oral administration. Drug Metab Dispos 2010;39(1):15-21
   PubMed Web of Science ®Google Scholar
• Ray-Coquard I, Blay JY, Italiano A, et al. Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study. Lancet Oncol 2012;13(11):1133-40
   PubMed Web of Science ®Google Scholar
• Brennan RC, Federico S, Bradley C, et al. Targeting the p53 pathway in retinoblastoma with subconjunctival Nutlin-3a. Cancer Res 2011;71(12):4205-13
   PubMed Web of Science ®Google Scholar
• Zhang Y, Xiong S, Li Q, et al. Tissue-specific and age dependent effect of global MDM2 loss. J Pathol 2014;233:380-91
   PubMed Web of Science ®Google Scholar
• Elison JR, Cobrinik D, Claros N, et al. Small molecule inhibition of HDM2 leads to p53-mediated cell death in retinoblastoma cells. Arch Ophthalmol 2006;124:1269-75
   PubMed Web of Science ®Google Scholar
• Laurie NA, Donovan SL, Shih CS, et al. Inactivation of the p53 pathway in retinoblastoma. Nature 2006;444(2):61-6
   PubMedGoogle Scholar
• Moysidis SN, Thanos A, Vavvas DG. Mechanisms of inflammation in proliferative vitreoretinopathy: from bench to bedside. Mediators Inflamm 2012;2012(5):1-11
   Google Scholar
• Lei H, Rheaume MA, Cui J, et al. A novel function of p53. A gatekeeper of retinal detachment. Am J Path 2012;181(3):866-74
   PubMed Web of Science ®Google Scholar
• Zhao Y, Bernard D, Wang S. Small Molecule Inhibitors of MDM2-p53 and MDMX-p53 Interactions as new cancer therapeutics. Biodiscovery 2013;8:4
   Google Scholar